{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:51:36Z","timestamp":1791726696636,"version":"4.3.4"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS107887"],"award-info":[{"award-number":["R01 NS107887"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS107887"],"award-info":[{"award-number":["R01 NS107887"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurosurg.","NEUROS"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>More than a million Americans harbor a cerebral cavernous angioma (CA), and those who suffer a prior symptomatic hemorrhage have an exceptionally high rebleeding risk. Preclinical studies show that atorvastatin blunts CA lesion development and hemorrhage through inhibiting RhoA kinase (ROCK), suggesting it may confer a therapeutic benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate whether atorvastatin produces a difference compared to placebo in lesional iron deposition as assessed by quantitative susceptibility mapping (QSM) on magnetic resonance imaging in CAs that have demonstrated a symptomatic hemorrhage in the prior year. Secondary aims shall assess effects on vascular permeability, ROCK activity in peripheral leukocytes, signal effects on clinical outcomes, adverse events, and prespecified subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The phase I\/IIa placebo-controlled, double-blinded, single-site clinical trial aims to enroll 80 subjects randomized 1-1 to atorvastatin (starting dose 80 mg PO daily) or placebo. Dosing shall continue for 24-mo or until reaching a safety endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>EXPECTED OUTCOMES<\/jats:title>\n                    <jats:p>The trial is powered to detect an absolute difference of 20% in the mean percent change in lesional QSM per year (2-tailed, power 0.9, alpha 0.05). A decrease in QSM change would be a signal of potential benefit, and an increase would signal a safety concern with the drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>With firm mechanistic rationale, rigorous preclinical discoveries, and biomarker validations, the trial shall explore a proof of concept effect of a widely used repurposed drug in stabilizing CAs after a symptomatic hemorrhage. This will be the first clinical trial of a drug aimed at altering rebleeding in CA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuros\/nyy539","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T07:18:55Z","timestamp":1539587935000},"page":"843-853","source":"Crossref","is-referenced-by-count":75,"title":["Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial"],"prefix":"10.1227","volume":"85","author":[{"given":"Sean P","family":"Polster","sequence":"first","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Stadnik","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L","family":"Akers","sequence":"additional","affiliation":[{"name":"Angioma Alliance, Norfolk, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cao","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A","family":"Christoforidis","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, The University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged D","family":"Fam","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D","family":"Flemming","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romuald","family":"Girard","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hobson","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I","family":"Koenig","sequence":"additional","affiliation":[{"name":"National Institute of Neurological Disorders and Stroke, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Koskim\u00e4ki","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lane","sequence":"additional","affiliation":[{"name":"Division of Brain Injury Outcomes, Department of Neurology, Johns Hopkins University Medical Institutions, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K","family":"Liao","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, The University of Chicago Medical Center, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Lee","sequence":"additional","affiliation":[{"name":"Angioma Alliance, Norfolk, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u00e1n B","family":"Lyne","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichol","family":"McBee","sequence":"additional","affiliation":[{"name":"National Institute of Neurological Disorders and Stroke, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Morrison","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of New Mexico, Albuquerque, New Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Piedad","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Shenkar","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sorrentino","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, The University of Chicago Medical Center, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Brain Injury Outcomes, Department of Neurology, Johns Hopkins University Medical Institutions, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J","family":"Whitehead","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A","family":"Zeineddine","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F","family":"Hanley","sequence":"additional","affiliation":[{"name":"Division of Brain Injury Outcomes, Department of Neurology, Johns Hopkins University Medical Institutions, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam A","family":"Awad","sequence":"additional","affiliation":[{"name":"Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12]]},"reference":[{"issue":"4","key":"bib1-20231011","first-page":"547","article-title":"Pathological heterogeneity of angiographically occult vascular malformations of the brain","volume":"33","author":"Robinson","year":"1993","journal-title":"Neurosurgery"},{"issue":"1","key":"bib2-20231011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00006123-199901000-00020","article-title":"A comparison of the clinical profile of cavernous malformations with and without associated venous malformations","volume":"44","author":"Abdulrauf","year":"1999","journal-title":"Neurosurgery"},{"issue":"6","key":"bib3-20231011","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1227\/01.NEU.0000249188.38409.03","article-title":"Spectrum of genotype and clinical manifestations in cerebral cavernous malformations","volume":"59","author":"Gault","year":"2006","journal-title":"Neurosurgery"},{"issue":"5","key":"bib4-20231011","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/neuros\/nyx091","article-title":"Synopsis of guidelines for the clinical management of cerebral cavernous malformations: consensus recommendations based on systematic literature review by the angioma alliance scientific advisory board clinical experts panel","volume":"80","author":"Akers","year":"2017","journal-title":"Neurosurgery"},{"issue":"3","key":"bib5-20231011","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1474-4422(12)70004-2","article-title":"Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study","volume":"11","author":"Al-Shahi Salman","year":"2012","journal-title":"The Lancet Neurology"},{"issue":"2","key":"bib6-20231011","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1474-4422(15)00303-8","article-title":"Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data","volume":"15","author":"Horne","year":"2016","journal-title":"The Lancet Neurology"},{"issue":"5","key":"bib7-20231011","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1227\/00006123-199305000-00005","article-title":"Factors predisposing to clinical disability in patients with cavernous malformations of the brain","volume":"32","author":"Robinson","year":"1993","journal-title":"Neurosurgery"},{"issue":"2","key":"bib8-20231011","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/jns.1997.87.2.0190","article-title":"Cerebral cavernous malformations: natural history and prognosis after clinical deterioration with or without hemorrhage","volume":"87","author":"Porter","year":"1997","journal-title":"J Neurosurg"},{"issue":"4","key":"bib9-20231011","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1084\/jem.20091258","article-title":"Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity","volume":"207","author":"Stockton","year":"2010","journal-title":"J Exp Med"},{"issue":"16","key":"bib10-20231011","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1074\/jbc.C109.097220","article-title":"Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype","volume":"285","author":"Borikova","year":"2010","journal-title":"J Biol Chem"},{"issue":"2","key":"bib11-20231011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nm.1911","article-title":"The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases","volume":"15","author":"Whitehead","year":"2009","journal-title":"Nat Med"},{"issue":"20","key":"bib12-20231011","doi-asserted-by":"crossref","first-page":"13301","DOI":"10.1074\/jbc.C900009200","article-title":"Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells","volume":"284","author":"Crose","year":"2009","journal-title":"J Biol Chem"},{"issue":"7597","key":"bib13-20231011","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nature17178","article-title":"Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2\/4 signalling","volume":"532","author":"Zhou","year":"2016","journal-title":"Nature"},{"issue":"16","key":"bib14-20231011","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1093\/hmg\/ddu153","article-title":"Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis","volume":"23","author":"McDonald","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"5","key":"bib15-20231011","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/hmg\/ddn420","article-title":"A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells","volume":"18","author":"Pagenstecher","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"4","key":"bib16-20231011","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/01.STR.0000157586.20479.fd","article-title":"Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion","volume":"36","author":"Gault","year":"2005","journal-title":"Stroke"},{"issue":"5","key":"bib17-20231011","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/hmg\/ddn430","article-title":"Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis","volume":"18","author":"Akers","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"2","key":"bib18-20231011","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/hmg\/ddq433","article-title":"A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease","volume":"20","author":"McDonald","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"3","key":"bib19-20231011","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2014.97","article-title":"Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations","volume":"17","author":"Shenkar","year":"2015","journal-title":"Genet Med"},{"issue":"5","key":"bib20-20231011","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0002-9440(10)63409-8","article-title":"Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations","volume":"165","author":"Plummer","year":"2004","journal-title":"Am J Pathol"},{"issue":"4","key":"bib21-20231011","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1227\/01.NEU.0000315862.24920.49","article-title":"Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models","volume":"63","author":"Shenkar","year":"2008","journal-title":"Neurosurgery"},{"issue":"7419","key":"bib22-20231011","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature11556","article-title":"A call for transparent reporting to optimize the predictive value of preclinical research","volume":"490","author":"Landis","year":"2012","journal-title":"Nature"},{"issue":"2","key":"bib23-20231011","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/STROKEAHA.111.625467","article-title":"Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease","volume":"43","author":"McDonald","year":"2012","journal-title":"Stroke"},{"issue":"1","key":"bib24-20231011","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/STROKEAHA.116.015013","article-title":"RhoA kinase inhibition with fasudil versus simvastatin in murine models of cerebral cavernous malformations","volume":"48","author":"Shenkar","year":"2017","journal-title":"Stroke"},{"issue":"4","key":"bib25-20231011","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.amjcard.2008.10.008","article-title":"Comparison of effects of rosuvastatin (10\u00a0mg) versus atorvastatin (40\u00a0mg) on rho kinase activity in caucasian men with a previous atherosclerotic event","volume":"103","author":"Rawlings","year":"2009","journal-title":"Am J Cardiol"},{"issue":"2","key":"bib26-20231011","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.atherosclerosis.2008.12.023","article-title":"Statins inhibit Rho kinase activity in patients with atherosclerosis","volume":"205","author":"Nohria","year":"2009","journal-title":"Atherosclerosis"},{"issue":"2","key":"bib27-20231011","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"bib28-20231011","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/RLI.0000000000000043","article-title":"Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping","volume":"49","author":"Tan","year":"2014","journal-title":"Invest Radiol"},{"issue":"7","key":"bib29-20231011","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3174\/ajnr.A4724","article-title":"Quantitative susceptibility mapping in cerebral cavernous malformations: clinical correlations","volume":"37","author":"Tan","year":"2016","journal-title":"Am J Neuroradiol."},{"issue":"1","key":"bib30-20231011","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3171\/2016.5.JNS16687","article-title":"Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations","volume":"127","author":"Girard","year":"2017","journal-title":"J Neurosurg"},{"issue":"4","key":"bib31-20231011","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/jmri.25831","article-title":"Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage","volume":"47","author":"Zeineddine","year":"2018","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"bib32-20231011","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/STROKEAHA.113.003548","article-title":"Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations","volume":"45","author":"Mikati","year":"2014","journal-title":"Stroke"},{"issue":"5","key":"bib33-20231011","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12975-013-0285-y","article-title":"Dynamic contrast-enhanced MRI evaluation of cerebral cavernous malformations","volume":"4","author":"Hart","year":"2013","journal-title":"Transl. Stroke Res"},{"issue":"10","key":"bib34-20231011","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/jcbfm.2015.98","article-title":"Vascular permeability in cerebral cavernous malformations","volume":"35","author":"Mikati","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"issue":"12","key":"bib35-20231011","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1161\/STROKEAHA.108.515544","article-title":"Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory Board","volume":"39","author":"Al-Shahi Salman","year":"2008","journal-title":"Stroke"},{"issue":"4","key":"bib36-20231011","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/neuros\/nyy108","article-title":"Trial readiness in cavernous angiomas with symptomatic hemorrhage (CASH)","volume":"84","author":"Polster","year":"2019","journal-title":"Neurosurgery"},{"issue":"8","key":"bib37-20231011","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3174\/ajnr.A4330","article-title":"Longitudinal mixed-effect model analysis of the association between global and tissue-specific brain atrophy and lesion accumulation in patients with clinically isolated syndrome","volume":"36","author":"Varosanec","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"bib38-20231011","doi-asserted-by":"crossref","first-page":"434","DOI":"10.22237\/jmasm\/1130803680","article-title":"Sample size calculation and power analysis of time-averaged difference","volume":"4","author":"Liu","year":"2005","journal-title":"J. Mod. App. Stat. Meth"},{"issue":"5","key":"bib39-20231011","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco","year":"2009","journal-title":"The Lancet Neurology"},{"issue":"4","key":"bib42-20231011","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JCO.2008.17.8905","article-title":"Monitoring for lack of benefit: a critical component of a randomized clinical trial","volume":"27","author":"Freidlin","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neurosurgery\/article-pdf\/85\/6\/843\/32778192\/nyy539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyy539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:50:49Z","timestamp":1786121449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyy539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1093\/neuros\/nyy539","relation":{},"ISSN":["0148-396X","1524-4040"],"issn-type":[{"value":"0148-396X","type":"print"},{"value":"1524-4040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]}}}